Literature DB >> 10677790

Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry.

S P Nielsen1, D Slosman, O H Sørensen, B Basse-Cathalinat, P De Cassin, C R Roux, P J Meunier.   

Abstract

The presence of Sr in bone influences bone mineral density (BMD) and content (BMC) measurements by dual-energy X-ray absorptiometry (DXA). This interaction is of interest, since strontium ranelate (S12911) demonstrated positive effects on bone metabolism in various animal models of osteoporosis, and is currently being evaluated for treatment of postmenopausal osteoporosis. The present in vitro study aimed to determine adjustment factors for DXA measurements of BMC and BMD at different Sr concentrations in order to estimate the corresponding values that would have been measured without Sr. A series of mixtures of Ca and Sr hydroxyapatites were prepared, with biologically relevant Sr/Ca ratios ranging from 0 to 3.5 mol/mol%, and a constant total concentration of divalent cations (145 mmol). The mixtures were conditioned in plastic dishes 4.5 cm in diameter, to obtain an areal density close to the human vertebral mineral density of 0.7-1.1 g/cm(2). DXA measurements of the mixtures were made with a wide range of different instruments and various acquisition modes. A direct linear relationship (r(2) > 0.99) was found between strontium content and overestimation of BMD and BMC. There were no significant differences in adjustment factors for BMC or BMD between the different machines or acquisition modes, and the presence of Sr in the water bath used to mimic soft tissues did not affect the accuracy and precision of the method. This demonstrates that reliable DXA determinations of BMD may be carried out in the presence of Sr, and may be interpreted in terms of calcium hydroxyapatite equivalent if the bone Sr content of the measured bone is known. The same adjustment factor (10% overestimation for 1 mol/mol% Sr) can be used for all presently available types of instrument and acquisition modes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10677790     DOI: 10.1016/s1094-6950(06)60402-2

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.963


  19 in total

1.  The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

Authors:  E T Middleton; S A Steel; M Aye; S M Doherty
Journal:  Osteoporos Int       Date:  2011-01-28       Impact factor: 4.507

2.  Comparison study of biomimetic strontium-doped calcium phosphate coatings by electrochemical deposition and air plasma spray: morphology, composition and bioactive performance.

Authors:  Ling Li; Xia Lu; Yizhi Meng; Christopher M Weyant
Journal:  J Mater Sci Mater Med       Date:  2012-04-18       Impact factor: 3.896

3.  Strontium ranelate for the treatment of osteoporosis.

Authors:  Ignac Fogelman; Glen M Blake
Journal:  BMJ       Date:  2005-06-18

4.  Bone: Strontium ranelate does not have an anabolic effect on bone.

Authors:  Glen M Blake; Ignac Fogelman
Journal:  Nat Rev Endocrinol       Date:  2013-10-22       Impact factor: 43.330

5.  Influence of Prevalent Vertebral Fracture on the Correlation between Change in Lumbar Spine Bone Mineral Density and Risk of New Vertebral Fracture: A Meta-Analysis of Randomized Clinical Trials.

Authors:  Tsuyoshi Kobayashi; Masayuki Kaneko; Mamoru Narukawa
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

6.  Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal.

Authors:  Roberto Cesareo; Clemente Napolitano; Mario Iozzino
Journal:  Int J Womens Health       Date:  2010-08-09

Review 7.  Monitoring strontium ranelate therapy in patients with osteoporosis.

Authors:  D L Kendler; J D Adachi; R G Josse; D O Slosman
Journal:  Osteoporos Int       Date:  2009-03-06       Impact factor: 4.507

8.  Relationship of blood lead levels to incident nonspine fractures and falls in older women: the study of osteoporotic fractures.

Authors:  Naila Khalil; Jane A Cauley; John W Wilson; Evelyn O Talbott; Lisa Morrow; Marc C Hochberg; Teresa A Hillier; Susan B Muldoon; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2008-09       Impact factor: 6.741

9.  Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Authors:  P J Meunier; C Roux; S Ortolani; M Diaz-Curiel; J Compston; P Marquis; C Cormier; G Isaia; J Badurski; J D Wark; J Collette; J Y Reginster
Journal:  Osteoporos Int       Date:  2009-01-20       Impact factor: 4.507

Review 10.  Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women.

Authors:  Natasha Jordan; Maurice Barry; Eithne Murphy
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.